[Serologic evaluation of treatment of chronic Chagas disease with allopurinol and itraconazole].
BACKGROUND
Chagas disease is endemic in Chile. Allopurinol and itraconazole have activity against Trypanosoma cruzi and are recommended for the treatment of chronic disease in adults.


OBJECTIVE
To evaluate the chemotherapeutic effects of allopurinol and itraconazole using conventional and non conventional serologic tests.


METHODS
Sera of 90 patients with chronic Chagas disease were studied before and after 9 to 11 months of treatment with allopurinol or itraconazole and after two months of treatment with placebo. Indirect immunofluorescence, ELISA and Western Blot analysis were the conventional serologic tests used and antibody dependent complement mediated lysis (CoML) the non conventional test.


RESULTS
There were no differences in ELISA and indirect immunofluorescence tests before and after therapy. Antigenic recognition profiles by Western Blot showed qualitative and quantitative differences in a small number of cases. CoML showed that the greater negativity was achieved in the Chagasic group treated with allopurinol or itraconazole that had a negative xenodiagnosis before drug treatment (35.8 and 61.6%, respectively).


CONCLUSIONS
There is a reversion of lytic activity in sera of patients with negative xenodiagnosis before treatment, suggesting the parasitemia could be an important parameter to be considered in the chemotherapy of Chagas disease.
Zulantay
I
I
Programa de Parasitología, Facultad de Medicina, Universidad de Chile.
Apt
W
W
Rodríguez
J
J
Venegas
J
J
Sánchez
G
G
D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D014355:Chagas Disease / Q000097:blood / Q000188:drug therapy*; D002648:Child; D002908:Chronic Disease; D005500:Follow-Up Studies; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008875:Middle Aged
D000981:Antiprotozoal Agents; D017964:Itraconazole; D000493:Allopurinol